Premio Martín Villar de Investigación en Hemostasia
- Organization:
- Laboratorios Grífols
- Category:
- Awards
- Scope:
- National Research Networks
- Start:
- Internal deadline:
- Official deadline:
- Description:
-
Objective
The Martín Villar Haemostasis Awards aim to support scientific excellence and innovation, and to engage both physicians and scientists who are early in their careers in investigating haemophilia and von Willebrand disease.
Beginning with the 2017 edition of the Martin Villar Awards, the Award introduces a new concept by providing 2 grants, for 1 project in Clinical Research and 1 project in Basic Research..
Requirements
Scientists or clinicians with innovative ideas relevant to hemostasis and blood coagulation disorders research are invited to submit their application. Applications are encouraged from both individuals and teams who may be conducting research at hospitals, universities or independent institutions.
- Applicants must submit an original research contribution to basic or clinical research in haemophilia or von Willebrand disease. Projects should be related to pathology or management with plasma-derived protein therapies in general, not associated with one particular commercial product.
- Applicants must present a focused project with goals that can be achieved within 12 months.
- Applicants must be employed or supported by a hospital, university or independent institution.
- Primary applicant must be under the age of 40 at the time point of LOI submission.
How to apply:
http://www.martinvillar-awards.com/en/web/martinvillar/application-form
Participants must submit a Letter of Intent (LOI), including:
- A brief resume or CV (of all investigators for a team application)
- Protocol summary
In case of interest, please contact FSJD Research's Department no later than 28th February 2020.
- Applicants must submit an original research contribution to basic or clinical research in haemophilia or von Willebrand disease. Projects should be related to pathology or management with plasma-derived protein therapies in general, not associated with one particular commercial product.